Form 4: Cogent Biosciences Director Acquires Stock Options in Lieu of Cash Compensation

Karen Jean Ferrante, a director at Cogent Biosciences, acquired 3,788 stock options in lieu of cash compensation on April 1, 2025.

Summary

• On April 1, 2025, Karen Jean Ferrante, a director at Cogent Biosciences, acquired 3,788 stock options.
• The options were granted in lieu of cash compensation for services as a director, according to the Issuer's non-employee director compensation plan.
• The exercise price of the stock options is $5.79.
• The options are exercisable from April 1, 2025, and expire on April 1, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard director compensation practice, aligning director interests with shareholders.

Positives

• A director taking compensation in stock options aligns their interests with those of shareholders.

Management Comments

• The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan.
• The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Industry Context

Director compensation packages often include stock options to incentivize long-term value creation and align director interests with shareholder interests. This is a common practice in the biotech industry.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation packages.
• The specific number of options and the exercise price are determined based on factors such as the company's size, market capitalization, and the director's role and responsibilities.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term success.
• The director benefits from potential future gains in the company's stock price.

Key Dates

Keywords

stock options, director compensation, Cogent Biosciences, COGT, Form 4, insider transaction